Kancera’s ROR-inhibitor provides higher specificity than competing products

On February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation Dr. Olin described how Kancera, in collaboration with...

Read More

Kancera file patents for ROR inhibitors against cancer

Kancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's ROR technology directed against both leukemia and solid tumors....

Read More

Kanceras strategy is given attention when global expertise in cancer gathers in Washington DC

Today Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts in oncology from both the pharmaceutical industry and academia....

Read More

iNovacia announces collaboration with Agios Pharmaceuticals

iNovacia AB, the provider of small molecule drug discovery services, today announced that it has entered into a high-throughput screening collaboration with Agios Pharmaceuticals, Cambridge (MA), USA.

Read More

Kancera strengthens its patent portfolio in cancer metabolism

Kancera report that the Company has registered a patent application for novel compounds targeting the energy metabolism of cancer. The new patent application covers a strategy to facilitate the uptake of substances in cancer cells. These synthetic molecules weaken...

Read More

iNovacia, GE Healthcare and scientists at Karolinska Institutet collaborate to advance drug discovery strategies

In an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance and nuclear magnetic resonance techniques have been cross-validated as...

Read More

Further clinical support for ROR1 as a diagnostic tool and therapeutic target

Kancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of this putative tumor target in patients with progressive stages...

Read More

Interim Report for Kancera AB (publ)

January 1 - September 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...

Read More

Notice of Extraordinary General Meeting Kancera AB

Aktieägarna i Kancera AB (publ) kallas härmed till extra bolagsstämma torsdagen den 10 november 2011 kl. 16.00 på Kilpatrick Townsend Advokatbyrås kontor, Hovslagargatan 5B, 5 tr i Stockholm.

Read More

iNovacia AB has developed active compounds as a step towards  treatment of a serious parasitic disease

iNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite Schistosoma have been developed. This parasite infects annually...

Read More